Answers are grounded in this paper and cite their sources.
The expansion of biomedical HIV prevention during the past decade represents one of the major public health successes of the HIV response. Oral pre-exposure prophylaxis (PrEP) is highly effective, and modelling studies support the cost-effectiveness of easy-access, risk-informed PrEP in epidemics in sub-Saharan Africa.1 Although more than 3·5 million people received PrEP globally at least once in 2023, with 2·6 million (>75%) of them in the African region, this number remains far less than the 2025 global target of 10 million people receiving PrEP.
No takes yet. Share an insight, caveat, or question.
Tara D. Mangal (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: